
Talacotuzumab
CAS No. 1826831-79-1
Talacotuzumab( —— )
Catalog No. M36759 CAS No. 1826831-79-1
Talacotuzumab (JNJ 56022473) is an IgG1 fully humanized CD123 neutralizing monoclonal antibody containing a modified Fc structure.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 755 | Get Quote |
![]() ![]() |
5MG | 1026 | Get Quote |
![]() ![]() |
10MG | 1378 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameTalacotuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionTalacotuzumab (JNJ 56022473) is an IgG1 fully humanized CD123 neutralizing monoclonal antibody containing a modified Fc structure.
-
DescriptionTalacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models.
-
In Vitro——
-
In VivoAnimal Model:Nonobese diabetic/severe combined immunodeficiency mice injected intravenously AML xenograft cells (AML-5)Dosage:300 μg Administration:IP; thrice weekly for 5 weeks Result:Resulted in a significant delay in tumor growth compared with an isotype control.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorInterleukin | Immunology/Inflammation related
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1826831-79-1
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. S J Busfield, et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014 Nov;28(11):2213-21.?
molnova catalog



related products
-
Monascin
Monascin is a kind of azaphilonoid pigments extracted from Monascus pilosus-fermented rice (red-mold rice).
-
Arjunetin
Arjunetin, an insect feeding-deterrent and growth inhibitor, shows antioxidant and anti-inflammatory activities.
-
7-Acetyllycopsamine
Lycopsamine `1-acetate is a bioactive chemical.